Company: BIAF
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001641172-25-013280
Chunk: 57

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 57
---
 to obtain a sufficient number of additional votes to approve the Reverse Stock Split Proposal, the Warrant Exercise Proposal, the Authorized Increase Proposal, and/or the Anti-Dilution Adjustment Proposal.

In the Adjournment Proposal, we are asking stockholders to authorize the holder of any proxy solicited by the Board to vote in favor of adjourning or postponing the Annual Meeting or any adjournment or postponement thereof. If our stockholders approve this proposal, we could adjourn or postpone the Annual Meeting, and any adjourned session of the Annual Meeting, to use the additional time to solicit additional proxies in favor of the Reverse Stock Split Proposal, the Warrant Exercise Proposal, the Authorized Increase Proposal, and/or the Anti-Dilution Adjustment Proposal.

Additionally, approval of the Adjournment Proposal could mean that, in the event we receive proxies indicating that holders of a majority of the number of shares present in person or represented by proxy at the Annual Meeting will vote against the Reverse Stock Split Proposal, the Warrant Exercise Proposal, the Authorized Increase Proposal, and/or Anti-Dilution Adjustment Proposal, we could adjourn or postpone the Annual Meeting without a vote on the Reverse Stock Split Proposal, the Warrant Exercise Proposal, the Authorized Increase Proposal, and/or the Anti-Dilution Adjustment Proposal and use the additional time to solicit the holders of those shares to change their vote in favor of the Reverse Stock Split Proposal, the Warrant Exercise Proposal, the Authorized Increase Proposal, and/or the Anti-Dilution Adjustment Proposal.

Interests of Directors and Executive Officers

Our directors and executive officers have no substantial interests, directly or indirectly, in the matters set forth in this proposal. However, as a condition to the closing of the best efforts public offering on May 7, 2025, our officers and directors executed support agreements, agreeing to vote in support of this Proposal No. 7, as well as the Authorized Increase Proposal (Proposal No. 5) and the Anti-Dilution Adjustment Proposal (Proposal No. 6).

Vote Required

The affirmative vote of the holders of a majority of the shares present in person or represented by proxy at the Annual Meeting is required to approve the Adjournment Proposal. Abstentions will have the same effect as a vote AGAINST the proposal. Broker non-votes are not expected for this proposal because we believe this matter is a routine matter. If there were to be any broker non-votes they would have no effect on this proposal.

| 29 |

<div align='center'>